Indivior (NASDAQ:INDV) Sees Strong Trading Volume – Time to Buy?

Indivior PLC (NASDAQ:INDV) shares saw unusually-strong trading volume on Friday . Approximately 8,737,425 shares were traded during mid-day trading, an increase of 312% from the previous session’s volume of 2,121,490 shares.The stock last traded at $31.0260 and had previously closed at $30.86.

Analyst Ratings Changes

Several analysts recently commented on INDV shares. Northland Securities set a $50.00 price target on shares of Indivior in a report on Tuesday, January 20th. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday, March 2nd. HC Wainwright increased their target price on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research note on Wednesday, December 3rd. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

Indivior Trading Down 0.5%

The firm has a market capitalization of $3.84 billion, a price-to-earnings ratio of 18.74 and a beta of 0.83. The company has a fifty day moving average price of $33.83 and a 200-day moving average price of $30.53.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.17. The firm had revenue of $358.00 million for the quarter, compared to the consensus estimate of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. As a group, sell-side analysts predict that Indivior PLC will post 1.22 EPS for the current fiscal year.

Insider Activity at Indivior

In other Indivior news, Director Mark Stejbach purchased 775 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director directly owned 16,847 shares in the company, valued at $596,215.33. This trade represents a 4.82% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Daniel A. Ninivaggi purchased 775 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director directly owned 16,923 shares in the company, valued at $598,904.97. This represents a 4.80% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 5,842 shares of company stock worth $203,342 over the last quarter.

Institutional Trading of Indivior

A number of institutional investors and hedge funds have recently made changes to their positions in INDV. Oaktree Capital Management LP boosted its stake in shares of Indivior by 2,241.6% during the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after acquiring an additional 246,776,273 shares in the last quarter. Divisadero Street Capital Management LP raised its stake in shares of Indivior by 2,372.5% in the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock valued at $81,072,000 after acquiring an additional 3,226,605 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in Indivior by 101.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after purchasing an additional 3,201,639 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Indivior in the 4th quarter worth approximately $82,687,000. Finally, Vanguard Group Inc. boosted its position in Indivior by 57.9% during the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after purchasing an additional 2,008,078 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.